|
TRIM56 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.46389999514207E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.1981999999966E-06 |
| Normal-vs-Stage2 |
4.015700E-04 |
| Normal-vs-Stage3 |
7.71079999850599E-08 |
| Normal-vs-Stage4 |
1.05179999998484E-06 |
| Stage1-vs-Stage2 |
9.797000E-01 |
| Stage1-vs-Stage3 |
2.145000E-01 |
| Stage1-vs-Stage4 |
2.153600E-01 |
| Stage2-vs-Stage3 |
4.035400E-01 |
| Stage2-vs-Stage4 |
3.305600E-01 |
| Stage3-vs-Stage4 |
7.639400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.23630000365461E-08 |
| Normal-vs-AfricanAmerican |
6.057400E-03 |
| Normal-vs-Asian |
4.07869999999866E-05 |
| Caucasian-vs-AfricanAmerican |
5.571800E-01 |
| Caucasian-vs-Asian |
7.047200E-01 |
| AfricanAmerican-vs-Asian |
4.363400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.10650002680546E-09 |
| Normal-vs-Female |
3.89160000002775E-07 |
| Male-vs-Female |
1.319960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.8866999999998E-05 |
| Normal-vs-Age(41-60Yrs) |
7.78040000204427E-08 |
| Normal-vs-Age(61-80Yrs) |
1.20589999985654E-07 |
| Normal-vs-Age(81-100Yrs) |
2.944500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.831160E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.157420E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.411800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.289400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.231000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.196200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.184430E-03 |
| Classical-VS-Follicular |
6.438100E-03 |
| Classical-VS-Other |
1.376370E-01 |
| Classical-VS-Normal |
1.7616899999906E-05 |
| Tall-VS-Follicular |
3.774600E-01 |
| Tall-VS-Other |
8.144000E-01 |
| Tall-VS-Normal |
2.52189999994101E-08 |
| Follicular-VS-Other |
5.537000E-01 |
| Follicular-VS-Normal |
2.66259999603946E-08 |
| Other-VS-Normal |
2.940400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.84379999946094E-07 |
| Normal-vs-N1 |
1.53627999999184E-05 |
| N0-vs-N1 |
4.662800E-01 |
|
|
